Can hormone pills light up hidden prostate cancer on scans?
NCT ID NCT05683964
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether standard hormone therapy (apalutamide, darolutamide, or enzalutamide) can increase the visibility of prostate cancer cells on PSMA PET/CT scans. About 9 men with recurrent prostate cancer will take the hormone pill for a few weeks and then get a scan. The goal is to see if the treatment makes cancer spots brighter or reveals new ones, which could help doctors better detect where the cancer has spread.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Androgen receptor antagonist (apalutamide, darolutamide, or enzalutamide)
- What this could lead to
- If successful, this could help doctors better time PSMA PET scans to detect prostate cancer spread earlier.
- What could go wrong
- This is a very small, early-phase study with only 9 people. It is designed to understand biology, not to test a new treatment, so direct patient benefits are unlikely.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can surgery boost control of spread prostate cancer?
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks